Paul Hastings formerly served as President, Chief Executive Officer, a member of the Board of Directors, and Chairman of the Board of OncoMed Pharmaceuticals from 2006 through January 1, 2018. Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT,Inc. Before this role, he served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. Prior to Axys, he was President of Chiron Biopharmaceuticals, and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics. Mr. Hastings currently serves on the Board of Directors at Relypsa Inc., a clinical-stage biopharmaceutical company, and the Bay Area Biosciences Association (Bay Bio). He also serves on the Board of Directors and as Executive Committee Chair of the Emerging Companies Section of the Biotechnology Industry Organization (BIO). In June 2013, Mr. Hastings was elected Lead Director of the Board of Directors at Pacira Pharmaceuticals, where he had been a Board member since June 2011. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island. Paul Hastings formerly served as President, Chief Executive Officer, a member of the Board of Directors, and Chairman of the Board of OncoMed Pharmaceuticals from 2006 through January 1, 2018. Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT,Inc. Before this role, he served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. Prior to Axys, he was President of Chiron Biopharmaceuticals, and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics. Mr. Hastings currently serves on the Board of Directors at Relypsa Inc., a clinical-stage biopharmaceutical company, and the Bay Area Biosciences Association (Bay Bio). He also serves on the Board of Directors and as Executive Committee Chair of the Emerging Companies Section of the Biotechnology Industry Organization (BIO). In June 2013, Mr. Hastings was elected Lead Director of the Board of Directors at Pacira Pharmaceuticals, where he had been a Board member since June 2011. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Oncology